SCHEMBL20047566

SCHEMBL20047566

CCC(C)(C)C(F)(F)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.39
THRB P10828 2/20 0.39
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
HIF1A Q16665 1/20 0.35
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
KMT2A Q03164 1/20 0.32
FFAR3 O14843 1/20 0.32
HMGCR P04035 1/20 0.31
CHRM1 P11229 1/20 0.31
TBXA2R P21731 1/20 0.31
ADRA1A P35348 1/20 0.31
KDM4C Q9H3R0 1/20 0.30
FAAH O00519 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15681364 0.79 ACLY (0.39) ACLYTHRBALDH1A1TSHRCYP2D6
SCHEMBL29789023 0.77 ACLY (0.43) ACLYTHRBALDH1A1TSHRCYP2D6
SCHEMBL7329032 0.77 CES2 (0.39) MEN1CYP1A2KMT2AFAAH
SCHEMBL23829806 0.76 ACLY (0.41) ACLYTHRBALDH1A1TSHRCYP2D6
SCHEMBL15281753 0.75 THRB (0.41) ACLYTHRBALDH1A1TSHRCYP2D6
SCHEMBL5523415 0.75 FFAR1 (0.43) ACLYTHRBALDH1A1TSHR
SCHEMBL15427365 0.75 THRB (0.41) ACLYTHRBALDH1A1TSHRCYP2D6
SCHEMBL7944771 0.75 FAAH (0.32) MEN1CYP1A2KMT2AFAAH
SCHEMBL1801444 0.75
SCHEMBL10898274 0.74 ACLY (0.39) ACLYTHRBALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-10-22 US disclosed
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof GPBAR1, SLC10A1, NR1H4 ACLY 1136/4885THRB 285/4885ALDH1A1 1577/4885
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF GPBAR1, SLC10A1, NR1H4 ACLY 1136/4885THRB 285/4885ALDH1A1 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.